Autolus(AUTL) - 2025 Q2 - Quarterly Results

Form 8-K Filing Details This section details the administrative information of the Form 8-K filing, including registrant identification and securities registration Registrant Information and Filing Context This section outlines the registrant's identification, report date, registered securities, and emerging growth company status for the Form 8-K filing - The report date is August 12, 2025, filed by Autolus Therapeutics plc[1] Registered Securities | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :---------------------------------------------------------- | :---------------- | :---------------------------------------- | | American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share | AUTL | The Nasdaq Global Select Market | | Ordinary shares, nominal value $0.000042 per share* | * | The Nasdaq Stock Market LLC* | - The registrant is not indicated as an emerging growth company[4] Item 2.02 Results of Operations and Financial Conditions This item reports Autolus Therapeutics plc's financial results for the quarter ended June 30, 2025, and a corporate update announced via press release - On August 12, 2025, Autolus Therapeutics plc announced its financial results for the quarter ended June 30, 2025, and provided a corporate update[5] - A copy of the press release is furnished as Exhibit 99.1 and incorporated by reference[5] - This information is furnished, not deemed 'filed' for Section 18 of the Exchange Act, and not incorporated by reference in other filings unless expressly set forth[6] Item 7.01 Regulation FD Disclosure This item discloses the use of an updated corporate presentation for the company's Q2 2025 results conference call - The Company will utilize an updated corporate presentation during its conference call on August 12, 2025, to discuss Q2 2025 results[7] - A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K[7] - Similar to Item 2.02, this information is furnished and not deemed 'filed' for Section 18 of the Exchange Act[8] Item 9.01 Financial Statements and Exhibits This section lists the exhibits accompanying the Form 8-K filing, including the referenced press release and corporate presentation Exhibits | Exhibit No. | Description of Exhibit | | :------------ | :-------------------------------------- | | 99.1 | Press release dated August 12, 2025 | | 99.2 | Corporate Presentation dated August 12, 2025 | | 104 | Cover Page Interactive Date File (embedded within the Inline XBRL document) | Signatures This section contains the official signature confirming the due authorization and submission of the report - The report was signed by Christian Itin, Ph.D., Chief Executive Officer of Autolus Therapeutics plc, on August 12, 2025[12]